Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
- 1 April 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 19 (4), 988-998
- https://doi.org/10.1158/1535-7163.MCT-19-0893
Abstract
The CD137 receptor plays a key role in mediating immune response by promoting T cell proliferation, survival, and memory. Effective agonism of CD137 has the potential to reinvigorate potent antitumor immunity either alone or in combination with other immune-checkpoint therapies. In this study, we describe the discovery and characterization of a unique CD137 agonist, 7A5, a fully human IgG1 Fc effector-null monoclonal antibody. The biological properties of 7A5 were investigated through in vitro and in vivo studies. 7A5 binds CD137, and the binding epitope overlaps with the CD137L binding site based on structure. 7A5 engages CD137 receptor and activates NF-kappa B cell signaling independent of cross-linking or Fc effector function. In addition, T cell activation measured by cytokine IFN gamma production is induced by 7A5 in peripheral blood mononuclear cell costimulation assay. Human tumor xenograft mouse models reconstituted with human immune cells were used to determine antitumor activity in vivo. Monotherapy with 7A5 inhibits tumor growth, and this activity is enhanced in combination with a PD-L1 antagonist antibody. Furthermore, the intratumoral immune gene expression signature in response to 7A5 is highly suggestive of enhanced T cell infiltration and activation. Taken together, these results demonstrate 7A5 is a differentiated CD137 agonist antibody with biological properties that warrant its further development as a cancer immunotherapy. [GRAPHICS]Other Versions
Funding Information
- Eli Lilly and Company
This publication has 36 references indexed in Scilit:
- Boosting Cancer Immunotherapy with Anti-CD137 Antibody TherapyClinical Cancer Research, 2015
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptorsNature Medicine, 2015
- The future of immune checkpoint therapyScience, 2015
- Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodiesThe Journal of Experimental Medicine, 2013
- 4-1BB Signaling Activates the T Cell Factor 1 Effector/β-Catenin Pathway with Delayed Kinetics via ERK Signaling and Delayed PI3K/AKT Activation to Promote the Proliferation of CD8+ T CellsPLOS ONE, 2013
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- The Bsister MADS Gene FST Determines Ovule Patterning and Development of the Zygotic Embryo and EndospermPLOS ONE, 2013
- Clinical targeting of the TNF and TNFR superfamiliesNature Reviews Drug Discovery, 2013
- T‐cell intrinsic effects of GITR and 4‐1BB during viral infection and cancer immunotherapyImmunological Reviews, 2011
- Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumorsNature Medicine, 1997